Literature DB >> 35013590

Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma - buying time or time to change?

Shankar Siva1,2, Alexander V Louie3.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35013590     DOI: 10.1038/s41585-021-00560-3

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.

Authors:  Shankar Siva; Mathias Bressel; Simon T Wood; Mark G Shaw; Sherene Loi; Shahneen K Sandhu; Ben Tran; Arun A Azad; Jeremy H Lewin; Katharine E Cuff; Howard Y Liu; Daniel Moon; Jeremy Goad; Lih-Ming Wong; Michael LimJoon; Jennifer Mooi; Sarat Chander; Declan G Murphy; Nathan Lawrentschuk; David Pryor
Journal:  Eur Urol       Date:  2021-12-23       Impact factor: 24.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.